Juvisync and Dry socket - a phase IV clinical study of FDA data
Summary:
We study 84 people who take Juvisync (simvastatin; sitagliptin phosphate) or have Dry socket. No report of Dry socket is found in people who take Juvisync.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Juvisync?
Juvisync has active ingredients of simvastatin; sitagliptin phosphate. eHealthMe is studying from 16 Juvisync users. Check the latest studies of Juvisync.
What is Dry Socket?
Dry socket (inflammation in the socket of a tooth) is found to be associated with 21 drugs and 42 conditions by eHealthMe. Check the latest studies of Dry socket.
No report is found.
Do you take Juvisync and have Dry socket?
- Check whether Dry socket is associated with a drug or a condition (FREE)
- Predict drug outcomes for up to one year with AI (FREE)
- Get an AI agent to monitor your drugs continuously (FREE)
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Juvisync:
- Juvisync (16 reports)
Dry socket treatments and more:
- Dry socket (68 reports)
How severe was Dry socket and when was it recovered:
Expand to all the drugs that have ingredients of simvastatin; sitagliptin phosphate:
Browse all side effects of Juvisync:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Dry socket:
Browse all the conditions that are associated with Dry socket:
How the study uses the data?
The study uses data from the FDA. It is based on simvastatin; sitagliptin phosphate (the active ingredients of Juvisync) and Juvisync (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Blood Glucose Increased and Glaucoma - now
- Tracheobronchitis and drugs of ingredients of meloxicam - 7 seconds ago
- Onychalgia and drugs of ingredients of carvedilol - 8 seconds ago
- Could Hydroxyzine cause Autoimmune Disorder? - 11 seconds ago
- Cyst and drugs of ingredients of abatacept - 11 seconds ago
- Drug interactions of Guaifenesin and Norco - 13 seconds ago
- Drug interactions of Vyvanse and Carvedilol - 19 seconds ago
- Doxycycline and Antidepressant Therapy for Men aged 40-49 - 22 seconds ago
- Doxycycline and Depression for Men aged 40-49 - 22 seconds ago
- Drug interactions of Voltaren and Carvedilol - 23 seconds ago